CSIMarket
 
Aprea Therapeutics Inc   (NASDAQ: APRE)
Other Ticker:  
 
 
Price: $3.3100 $-0.28 -7.799%
Day's High: $3.5 Week Perf: -18.41 %
Day's Low: $ 3.31 30 Day Perf: -9.44 %
Volume (M): 29 52 Wk High: $ 8.85
Volume (M$): $ 97 52 Wk Avg: $4.34
Open: $3.49 52 Wk Low: $2.15



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 6
 Employees 34
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Aprea Therapeutics Inc
Aprea Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel cancer treatments. The company is primarily engaged in the research and development of small molecule drugs that restore the tumor suppressor protein p53 to its normal function. p53 is a crucial protein involved in regulating cell division and preventing the formation of cancerous tumors.

Aprea Therapeutics' lead candidate is called APR-246, which has shown promising results in clinical trials for various types of cancers, including hematologic malignancies and solid tumors. APR-246 works by reactivating mutated or inactivated p53 to induce apoptosis, or programmed cell death, in cancer cells while sparing healthy cells.

The company also has other research programs focused on addressing different aspects of p53 biology through drug discovery efforts. Aprea Therapeutics aims to develop innovative therapies that can significantly impact the lives of patients with cancer and improve treatment options.

Founded in 2003 and headquartered in Boston, Massachusetts, Aprea Therapeutics has collaborations and partnerships with various academic institutions, as well as pharmaceutical and biotechnology companies. The company's advancements in p53 biology and the development of APR-246 have garnered significant attention in the field of oncology.


   Company Address: 3805 Old Easton Road Doylestown 18902 PA
   Company Phone Number: 463-9385   Stock Exchange / Ticker: NASDAQ APRE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.31%    
BPMC   -7.97%    
MEIP   -3.57%    
RIGL   -8.76%    
SUPN   -2.1%    
WVE   -14.95%    
• View Complete Report
   



Clinical Study

Aprea Therapeutics, a prominent player in the field of oncology, has strategically advanced its clinical an...

Published Mon, Dec 30 2024 12:54 AM UTC

Aprea Therapeutics Advances in Oncology: ATRN-119 Dual Dosing Approach and Promising Next-Gen Inhibitors Aprea Therapeutics, a prominent player in the field of oncology, has strategically advanced its clinical and research efforts by implementing innovative dosing strategies and unveiling significant updates on its promising drug pipeline. The company recently announced a sh...

Announcement

Aprea Therapeutics Navigates Financial Setbacks While Showcasing Scientific Progress at EORTC-NCI-AACR Conference

Published Thu, Oct 10 2024 12:30 PM UTC

In the ever-competitive healthcare sector, Aprea Therapeutics Inc finds itself at a pivotal moment. Recently, the company recorded a cumulative net loss of $13 million over the twelve months ending in the second quarter of 2024. This loss correlates with a negative return on investment (ROI) of -53.33%, placing Aprea in a challenging position, especially when compared to the...

Management Changes

Aprea Therapeutics Announces Engagement of Dr. Philippe Pultar as Senior Medical Advisor to Lead Development of WEE1 Inhibitor APR-1051 Amid New Clinical Trial Initiatives,

Published Wed, Oct 9 2024 12:30 PM UTC

Aprea Therapeutics Expands Expertise with Appointment of Philippe Pultar, MD, to Lead WEE1 Clinical Development Amid New Trial InitiativesAprea Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in precision oncology through the innovative concept of synthetic lethality, has made significant strides in its quest to advance cancer treatment options. On...

Clinical Study

Advancing Precision Oncology Aprea Therapeutics Harnesses the Power of DNA Damage Response in Cancer Treatment

Published Mon, Jun 17 2024 12:30 PM UTC

In a recent development, Aprea Therapeutics, a clinical-stage biopharmaceutical company dedicated to precision oncology through synthetic lethality, announced the initiation of the ACESOT-1051 Phase 1 trial. The trial aims to evaluate the potential of their highly selective oral WEE1 inhibitor, APR-1051, as a cutting-edge treatment for Cyclin E-overexpressing cancers.First P...

Aprea Therapeutics Inc

APREA Therapeutics Inc Reports Enhanced Operating Shortfall of $-4.6 Million in Latest Fiscal Period

As the earnings cycle progresses and more companies report their financial results, Aprea Therapeutics Inc stands out as a beacon of hope in the Major Pharmaceutical Preparations industry. With an operating shortfall of $-3.14967 million for the most recent fiscal period, Aprea Therapeutics Inc has shown significant improvement from the same period a year ago. This positive trend has analysts buzzing with optimism about the company's future prospects.
One key highlight is the decrease in operating deficit, from $-4.622503 million in the previous year to $-3.14967 million in the current period. This demonstrates a clear path towards financial recovery and stability for Aprea Therapeutics Inc. Additionally, the reduction in losses from $-4.380 million to $-2.810 million further solidifies the company's progress in improving its financial performance.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com